Models:
Joseph Gordon
joseph-gordon/
ClinicalTrialsElig
0
Downloads: 1
[c09aa8]: / clusters / ordered9kclusters / clust_837.txt

Download this file

17 lines (16 with data), 2.1 kB 

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
16
Prior treatment with anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway-targeting agents

Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents

Prior treatment with anti-PD-1, CTLA-4, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

Prior treatment with a CD137 agonists, anti-CTLA4 (except melanoma), anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents

Prior treatment with anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway targeting agents

Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists, anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents

Prior treatment with anti-PD-1, and CTLA-4, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

Prior treatment with anti-CTLA-4 therapeutic antibody or pathway-targeting agents

Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

Prior exposure to immunotherapy (either as a single agent or in combination) including but not limited to CD137 or OX40 agonists, anti-CTLA-4, anti-PD-1, or anti-PD-L1, anti-PD-L2 antibody or pathway-targeting agents

Prior treatment with anti-PD-1, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or anti-PD-L1 therapeutic antibody or pathway-targeting agents

Prior treatment with CD137 agonists, anti- cytotoxic T-lymphocyte-associated protein 4, anti-PD-1, or anti-PDL1 therapeutic antibody or pathway targeting agents; prior IFN alpha or IL-2 is allowed following 4 week washout from treatment end date

Prior treatment with CD137 agonists, anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway-targeting agents

Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents